Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanqi Huoluo Plaster is a Traditional Chinese Medicine (TCM) topical formulation developed by Guangzhou University of Chinese Medicine. It is primarily indicated for the treatment of acute closed soft tissue injuries characterized by the TCM pattern of qi stagnation and blood stasis. The formulation likely contains *Panax notoginseng* (Sanqi) as a key active ingredient, which is traditionally used to resolve blood stasis, reduce swelling, and alleviate pain. It is administered as a topical plaster to the affected area to promote functional recovery and provide pain relief. The drug has been evaluated in randomized, double-blind, placebo-controlled Phase II clinical trials in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanqi Huoluo Plaster.